IL-13 Induced Gene Signature for Eosinophilic Esophagitis

IL-13 Induced Gene Signature for Eosinophilic Esophagitis

(CHMC Ref. Id: 2007-0811)

Overview:

Eosinophilic esophagitis (EE) is an emerging worldwide disease.  The current treatment for EE is with swallowed glucocorticoids, however, only a subset of EE patients experience remission from the disease following treatment with topical steroids.  Dr. Marc Rothenberg has identified an esophageal transcriptome characterized by several genes, including eotaxin-3, differentially expressed and conserved between individuals which can be largely reversed with glucocorticoid treatment. 

Applications:

• Treatment of EE by application of glucocorticoid
• Methods of diagnosing EE by determining the presence of IL-13 mRNA and IL-4 mRNA
• Methods of diagnosis of EE by identifying an in vivo IL-13-induced transcriptome
• Method of determining effectiveness of a treatment for EE

Advantages:

• More effective treatment of EE
• Ability to determine effectiveness of a treatment for EE

Patent Information:

• Patent Applications Pending

Cincinnati Children's Lead Inventor:

Marc E. Rothenberg, M.D., Ph.D.